<DOC>
	<DOCNO>NCT02219217</DOCNO>
	<brief_summary>The purpose study look level three HIV medication : dolutegravir , elvitegravir cobicistat blood drug intake stop order understand long drug persist blood . The study specifically look blood level three drug take every day 10 day dolutegravir first stage combination elitegravir cobicistat second stage . If participant decides take part , duration study 38 day plus screening visit take place 28 day prior start study , follow visit take place 7 14 day last dose study medication . This study randomise mean participant receive study medication order . The participant study doctor know study medication participant take time study .</brief_summary>
	<brief_title>SSAT061 : PK DTG EVT/COBI Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Inclusion Criteria The ability understand sign write informed consent form , prior participation screening procedure must willing comply study requirement Male nonpregnant , nonlactating female Between 18 65 year , inclusive Body Mass Index ( BMI ) 18 35 kg/m2 , inclusive ALT , alkaline phosphatase bilirubin 1.5xULN ( isolate bilirubin great 1.5xULN acceptable bilirubin fractionate direct bilirubin lesser 35 per cent ) . A single repeat allow eligibility determination . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study period least 12 week study A female may eligible enter participate study : nonchildbearing potential define either postmenopausal ( 12 month spontaneous amenorrhea 45 year age ) physically incapable become pregnant document tubal ligation , hysterectomy bilateral oophorectomy , childbearing potential negative pregnancy test Screening Day 1 agrees use one follow method contraception avoid pregnancy : ( please see protocol ) Willing consent personal detail enter onto TOPS database Willing provide proof identity photographic ID screen subsequent visit Registered GP UK Exclusion Criteria Any clinically significant acute chronic medical illness Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG clinical laboratory determination Positive blood screen hepatitis B surface antigen C antibody Positive blood screen HIV1 2 antibody/antigen assay Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) History presence allergy DTG excipients ( DMannitol , Microcystalline Cellulose , Povidone , Croscarmellose Sodium , Sodium Stearyl Fumarate , Talc , white film coat ) Current recent ( within 3 month ) gastrointestinal disease Known intolerance lactose monohydrate , sunset yellow aluminium lake ( E110 ) , patient galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption Clinically relevant alcohol drug use ( positive urine drug screen ) history alcohol drug use consider Investigator sufficient hinder compliance treatment , followup procedure evaluation adverse event . Smoking permit , tobacco intake remain consistent throughout study Exposure investigational drug ( placebo ) participation clinical study involve donation blood sample within 3 month first dose study drug Use drug ( unless approve Investigator ) , include overthecounter medication herbal preparation , within two week prior first dose study drug , unless approved/prescribed Principal Investigator know interact study drug . Females childbearing potential without use effective nonhormonal birth control method , willing continue practise birth control method least 12 week end treatment period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>